Developer docs
API playgroundTry for free, no card

Search company profiles

HLB Biostep

Full company profile

uuid004f4vv

Namestring
HLB Biostep
Legal namestring
HLB bioStep Co., Ltd.
Websiteurl
hlbbiostep.com
Company typeenum
Public
Founded yearint
2012
Descriptiontext

HLB bioStep Co., Ltd. (KOSDAQ: 278650) is a South Korean non-clinical contract research organization (CRO) founded in 2012 as Korea's first specialized efficacy evaluation institution, headquartered in a 11,048.69 m² Songdo Research Center in Incheon. The company runs animal-based efficacy and safety studies across rodents, rabbits, dogs, pigs, guinea pigs, and primates using a fleet of high-spec imaging equipment (GE Signa Pioneer MRI, Siemens Somatom Emotion CT, PerkinElmer Quantum GX Micro-CT, Siemens Artis Zee C-arm, IVIS Spectrum) and validated disease models spanning xenograft and syngeneic oncology, metabolic, CNS, bone, ophthalmic, and other therapeutic areas. It also operates an in-house biological sample analysis center using LC-MS/MS (TQ 6500+/5500+), flow cytometry, RT-PCR, and automated workstations, a bio-infrastructure lab consulting and construction unit covering GLP/LMO/BSL facility design and licensing, and a veterinary drug non-clinical and clinical trial service designated by the Animal and Plant Quarantine Agency.

The company generates revenue through project-based professional services contracts with pharmaceutical and biotech firms (primary segment), lab construction clients across pharma/medical-device/chemical/food industries, and animal health companies; pricing is per-project and not publicly disclosed. Go-to-market is predominantly direct enterprise sales supported by a website inquiry system, industry conference participation (e.g., BioUSA 2024), and an annual Partnering Day event. Since HLB Group became the largest shareholder in June 2022 and the company was rebranded from Knotus to HLB bioStep in March 2023, the company has pursued inorganic growth — most notably acquiring GLP toxicology specialist KroEn (renamed HLB Biocode) in April 2024 — and has built a partnership network spanning Arontier (AI drug development, Dec 2023), Gradient Bioconversion (organoid platforms, June 2024), Chiron (animal-alternative testing, Oct 2025), and several Korean hospitals and universities, while operating as a KOSDAQ-listed entity with publicly disclosed share price but no publicly reported revenue.

Short descriptiontext

HLB Biostep is South Korea's first specialized non-clinical efficacy evaluation CRO, providing animal-based efficacy and safety testing, bioanalytical services, GLP lab consulting, and veterinary drug trials to pharmaceutical, biotech, and animal health companies from its Songdo, Incheon research center.

Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
HeadquartersIncheon, South Korea
HQ citystring
Incheon
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
non-clinical CRO services, efficacy evaluation, animal model studies, biological sample analysis, bio-infrastructure construction
Industry3 codes
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAFAA
In Vivo Pharmacology (Efficacy/PD Models)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAGAAAC
Toxicology & Safety Assessment CROs (GLP)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Testing Laboratories and Services541380
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Testing Laboratories8734
Product category
Non-Clinical Contract Research (CRO)
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Non-Clinical CRO Services (Efficacy & Safety Testing)
TypeProfessional Services
Description

Project-based contract research for pharmaceutical and biotech companies conducting non-clinical efficacy and safety evaluations in animal models. Revenue is generated through per-project fees based on study design complexity, species used, and number of endpoints. Core revenue driver.

hlbbiostep.com
2Bio-infrastructure Lab Consulting & Construction
TypeProfessional Services
Description

One-stop consulting and construction services for laboratory and animal facility setup including design, GLP/BSL certification support, validation, and equipment supply. Revenue generated through project-based contracts for facility construction and consulting engagements.

hlbbiostep.com
3Veterinary Drug Development Services
TypeProfessional Services
Description

Non-clinical and clinical trial services for veterinary drug development, designated by the Animal and Plant Quarantine Agency. Includes consulting on approval procedures and direct clinical trial performance, serving animal pharmaceutical companies.

hlbbiostep.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

HLB Biostep is Korea's first specialized non-clinical efficacy evaluation CRO, providing veterinary science-based preclinical testing services for pharmaceutical, biotech, and veterinary drug developers. Core offerings include animal-model-based efficacy evaluation across xenograft, syngeneic, and disease models; biological sample analysis using LC-MS/MS, flow cytometry, and PCR; bio-infrastructure lab design, construction, and validation; and designated veterinary drug non-clinical and clinical trial services. Services are delivered at a 11,048.69 m² Songdo research facility equipped with MRI, CT, Micro-CT, C-arm, and IVIS imaging platforms.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Over 1,000 experiments conducted annually with accumulated experimental know-how and data
+1 more record
Product overview1 text field

HLB Biostep operates as Korea's No.1 non-clinical CRO specializing in efficacy evaluation. The company offers an integrated service portfolio comprising: (1) Non-Clinical CRO Services providing animal-based efficacy testing across multiple therapeutic areas using established disease models; (2) Biological Sample Analysis using advanced analytical platforms (LC-MS/MS, Flow cytometry, PCR, Microplate readers); (3) Lab Consulting for bio-infrastructure construction offering one-stop facility development from planning through validation; and (4) Veterinary Drug Services for non-clinical and clinical trials designated by the Animal and Plant Quarantine Agency. The portfolio is augmented by an acquired GLP toxicity testing company (Kroen/HLB Biocode) and partnerships for next-generation organoid-based evaluation platforms.

Product and service4 records
1Non-Clinical CRO Services (비임상 CRO사업)
CategoryNon-clinical contract research
Description

Veterinary science-based non-clinical study services for new drug development, providing efficacy evaluation across cancer, bone, brain, metabolic, ophthalmologic, articular, and other therapeutic areas using xenograft, syngeneic, orthotopic, and disease-specific animal models in rodent, rabbit, dog, pig, and primate species. Targeted at pharmaceutical and biotechnology companies advancing drug candidates through preclinical development.

2Biological Sample Analysis (생체시료분석)
CategoryBioanalytical services
Description

Bioanalysis services using LC-MS/MS (TQ 6500+, TQ 5500+), flow cytometry (NovoCyte), real-time PCR (CFX96 Touch), microplate readers (Synergy H1), and automated workstations (Biomek i5) for pharmacokinetic, biomarker, and bioanalytical studies supporting drug development. Targeted at pharmaceutical and biotech clients requiring accurate and reliable analytical data for candidate characterization.

3Bio-infrastructure Lab Consulting & Construction (바이오인프라구축사업)
CategoryBio-infrastructure construction and consulting
Description

One-stop service for laboratory and animal facility construction including consulting, design, construction, testing and balancing (TAB), fumigation, maintenance, equipment supply, and validation for GLP, LMO, and BSL facilities. Targeted at pharmaceutical, medical device, chemical, pesticide, and food companies building or upgrading testing facilities.

4Veterinary Drug Services (동물의약품)
CategoryVeterinary drug development services
Description

Non-clinical and clinical trial services for veterinary drugs, designated by the Animal and Plant Quarantine Agency, including consulting on approval procedures, data review, and direct clinical trial performance for animal pharmaceutical companies. Targeted at animal health and veterinary pharmaceutical developers seeking regulatory-grade trial support.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-27
Description

HLB Biostep and Chiron partnered to develop next-generation non-clinical testing platforms, focusing on animal-alternative technologies to build next-gen efficacy evaluation platforms.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-05-05
Description

Barunseong Hospital signed a preclinical trial contract with HLB Biostep and HLB Biocode, combining clinical expertise with non-clinical testing capabilities.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-04-28
Description

HLB Biostep and KIT (Korea Institute of Toxicology) cooperated to build a joint research system for non-human primate (primate) testing, enhancing capabilities in primate-based preclinical studies.

4Gradient Bioconversion
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-06-13
Description

HLB Biostep and Gradient Bioconversion partnered for the commercialization of patient-derived organoid-based drug evaluation platforms, enabling more personalized and physiologically relevant pre-clinical testing.

hlbbiostep.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-04-26
Description

HLB Biostep and BNH Investment signed an MOU and hosted a Partnering Day event to identify promising biotech ventures for investment and strategic partnership opportunities.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-12-27
Description

HLB Biostep and Arontier entered into a comprehensive business cooperation agreement to accelerate AI-driven drug development. The partnership aims to leverage AI technologies across HLB Biostep's non-clinical testing capabilities.

7Ajou University Medical Center (아주대의료원)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-11-20
Description

HLB Biostep signed an agreement with Ajou University Medical Center for efficacy evaluation of mental and behavioral disorder diseases, combining clinical research expertise with non-clinical testing.

hlbbiostep.com
8Seoul Asan Hospital & Jeonbuk National University Hospital
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-05-10
Description

HLB Biostep signed efficacy evaluation agreements with Seoul Asan Hospital and Jeonbuk National University Hospital, enabling collaborative research combining clinical and non-clinical expertise.

hlbbiostep.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

BasgenBio is partnering with Yonsei University (alongside Dankook University) to mine clinical and omics datasets for drug targets. Listed here as a partner connected to BasgenBio's ecosystem which HLB bioStep is invested in.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

BasgenBio is partnering with Dankook University alongside Yonsei University to mine clinical and omics datasets. Listed as a partner in the broader ecosystem connected to HLB bioStep's investment in BasgenBio.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Integrated preclinical CRO with strong in vivo efficacy, DMPK, and safety assessment capabilities. Comparable service mix and customer focus on innovative drug developers.

TypeDirect peer
Description

Major Asian-headquartered preclinical CRO offering in vivo pharmacology, DMPK, and toxicology. Comparable service breadth and target customer base of global pharma/biotech sponsors.

TypeBroad incumbent
Description

Global testing services group with preclinical and bioanalytical capabilities alongside much broader food, environmental, and pharma testing. Comparable bioanalytical and preclinical testing services as part of a much wider portfolio.

TypeEmerging player
Description

China-based preclinical CRO with proprietary humanized mouse models and in vivo efficacy services. Comparable preclinical efficacy offering with a strong emerging-player focus on next-gen disease models.

5Labcorp (Labcorp Drug Development / Covance)
TypeBroad incumbent
Description

Diversified CRO offering preclinical and clinical services alongside diagnostics. Comparable preclinical efficacy/safety offering as one component of a much broader portfolio.

TypeDirect peer
Description

China-based preclinical CRO offering in vivo efficacy, PK/PD, and toxicology services. Comparable preclinical CRO service model targeting pharma/biotech sponsors globally.

TypeDirect peer
Description

Preclinical CRO specializing in oncology in vivo models including xenograft and syngeneic tumor models — a core capability area that directly overlaps with HLB bioStep's anti-cancer efficacy evaluation services.

8ICR (International Contract Research)
TypeDirect peer
Description

UK-headquartered preclinical CRO providing in vivo efficacy and safety studies in multiple species. Directly comparable core CRO service model.

TypeDirect peer
Description

U.S.-based preclinical CRO providing animal model services, toxicology, and research models. Closely comparable in vivo efficacy/safety testing business model.

TypeDirect peer
Description

Global leader in preclinical CRO services including in vivo efficacy and safety studies across rodent and large-animal models. Highly comparable end-to-end preclinical offering serving pharma and biotech clients.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

HLB Biostep

Non-Clinical Contract Research (CRO)hlbbiostep.com

HLB Biostep is South Korea's first specialized non-clinical efficacy evaluation CRO, providing animal-based efficacy and safety testing, bioanalytical services, GLP lab consulting, and veterinary drug trials to pharmaceutical, biotech, and animal health companies from its Songdo, Incheon research center.

What HLB Biostep does

HLB bioStep Co., Ltd. (KOSDAQ: 278650) is a South Korean non-clinical contract research organization (CRO) founded in 2012 as Korea's first specialized efficacy evaluation institution, headquartered in a 11,048.69 m² Songdo Research Center in Incheon. The company runs animal-based efficacy and safety studies across rodents, rabbits, dogs, pigs, guinea pigs, and primates using a fleet of high-spec imaging equipment (GE Signa Pioneer MRI, Siemens Somatom Emotion CT, PerkinElmer Quantum GX Micro-CT, Siemens Artis Zee C-arm, IVIS Spectrum) and validated disease models spanning xenograft and syngeneic oncology, metabolic, CNS, bone, ophthalmic, and other therapeutic areas. It also operates an in-house biological sample analysis center using LC-MS/MS (TQ 6500+/5500+), flow cytometry, RT-PCR, and automated workstations, a bio-infrastructure lab consulting and construction unit covering GLP/LMO/BSL facility design and licensing, and a veterinary drug non-clinical and clinical trial service designated by the Animal and Plant Quarantine Agency.

The company generates revenue through project-based professional services contracts with pharmaceutical and biotech firms (primary segment), lab construction clients across pharma/medical-device/chemical/food industries, and animal health companies; pricing is per-project and not publicly disclosed. Go-to-market is predominantly direct enterprise sales supported by a website inquiry system, industry conference participation (e.g., BioUSA 2024), and an annual Partnering Day event. Since HLB Group became the largest shareholder in June 2022 and the company was rebranded from Knotus to HLB bioStep in March 2023, the company has pursued inorganic growth — most notably acquiring GLP toxicology specialist KroEn (renamed HLB Biocode) in April 2024 — and has built a partnership network spanning Arontier (AI drug development, Dec 2023), Gradient Bioconversion (organoid platforms, June 2024), Chiron (animal-alternative testing, Oct 2025), and several Korean hospitals and universities, while operating as a KOSDAQ-listed entity with publicly disclosed share price but no publicly reported revenue.

HLB Biostep firmographics

Firmographics
Name
HLB Biostep
Legal name
HLB bioStep Co., Ltd.
Website
https://hlbbiostep.com
Company type
Public
Founded year
2012
Operating status
Operating
Short description
HLB Biostep is South Korea's first specialized non-clinical efficacy evaluation CRO, providing animal-based efficacy and safety testing, bioanalytical services, GLP lab consulting, and veterinary drug trials to pharmaceutical, biotech, and animal health companies from its Songdo, Incheon research center.
Ownership category
akta.pro rank

HLB Biostep industry classification

Industry
Product category
Non-Clinical Contract Research (CRO)
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Testing Laboratories and Services (541380)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)
akta.pro industry
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAFAA
In Vivo Pharmacology (Efficacy/PD Models)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAGAAAC
Toxicology & Safety Assessment CROs (GLP)

Keywords

  • Non-clinical CRO services
  • Efficacy evaluation
  • Animal model studies
  • Biological sample analysis
  • Bio-infrastructure construction

Where HLB Biostep is headquartered

Location

Headquarters

HQ city
Incheon
HQ country
South Korea
HQ region
Asia

Offices1 record

Markets served

HLB Biostep business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

  1. Non-Clinical CRO Services (Efficacy & Safety Testing): Project-based contract research for pharmaceutical and biotech companies conducting non-clinical efficacy and safety evaluations in animal models. Revenue is generated through per-project fees based on study design complexity, species used, and number of endpoints. Core revenue driver.
  2. Bio-infrastructure Lab Consulting & Construction: One-stop consulting and construction services for laboratory and animal facility setup including design, GLP/BSL certification support, validation, and equipment supply. Revenue generated through project-based contracts for facility construction and consulting engagements.
  3. Veterinary Drug Development Services: Non-clinical and clinical trial services for veterinary drug development, designated by the Animal and Plant Quarantine Agency. Includes consulting on approval procedures and direct clinical trial performance, serving animal pharmaceutical companies.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

HLB Biostep product offering

Product offering

Core offering

HLB Biostep is Korea's first specialized non-clinical efficacy evaluation CRO, providing veterinary science-based preclinical testing services for pharmaceutical, biotech, and veterinary drug developers. Core offerings include animal-model-based efficacy evaluation across xenograft, syngeneic, and disease models; biological sample analysis using LC-MS/MS, flow cytometry, and PCR; bio-infrastructure lab design, construction, and validation; and designated veterinary drug non-clinical and clinical trial services. Services are delivered at a 11,048.69 m² Songdo research facility equipped with MRI, CT, Micro-CT, C-arm, and IVIS imaging platforms.

Product overview

HLB Biostep operates as Korea's No.1 non-clinical CRO specializing in efficacy evaluation. The company offers an integrated service portfolio comprising: (1) Non-Clinical CRO Services providing animal-based efficacy testing across multiple therapeutic areas using established disease models; (2) Biological Sample Analysis using advanced analytical platforms (LC-MS/MS, Flow cytometry, PCR, Microplate readers); (3) Lab Consulting for bio-infrastructure construction offering one-stop facility development from planning through validation; and (4) Veterinary Drug Services for non-clinical and clinical trials designated by the Animal and Plant Quarantine Agency. The portfolio is augmented by an acquired GLP toxicity testing company (Kroen/HLB Biocode) and partnerships for next-generation organoid-based evaluation platforms.

Differentiator

Problem solved

Functional benefit

Products and services

  • Non-Clinical CRO Services (비임상 CRO사업) Veterinary science-based non-clinical study services for new drug development, providing efficacy evaluation across cancer, bone, brain, metabolic, ophthalmologic, articular, and other therapeutic areas using xenograft, syngeneic, orthotopic, and disease-specific animal models in rodent, rabbit, dog, pig, and primate species. Targeted at pharmaceutical and biotechnology companies advancing drug candidates through preclinical development.
  • Biological Sample Analysis (생체시료분석) Bioanalysis services using LC-MS/MS (TQ 6500+, TQ 5500+), flow cytometry (NovoCyte), real-time PCR (CFX96 Touch), microplate readers (Synergy H1), and automated workstations (Biomek i5) for pharmacokinetic, biomarker, and bioanalytical studies supporting drug development. Targeted at pharmaceutical and biotech clients requiring accurate and reliable analytical data for candidate characterization.
  • Bio-infrastructure Lab Consulting & Construction (바이오인프라구축사업) One-stop service for laboratory and animal facility construction including consulting, design, construction, testing and balancing (TAB), fumigation, maintenance, equipment supply, and validation for GLP, LMO, and BSL facilities. Targeted at pharmaceutical, medical device, chemical, pesticide, and food companies building or upgrading testing facilities.
  • Veterinary Drug Services (동물의약품) Non-clinical and clinical trial services for veterinary drugs, designated by the Animal and Plant Quarantine Agency, including consulting on approval procedures, data review, and direct clinical trial performance for animal pharmaceutical companies. Targeted at animal health and veterinary pharmaceutical developers seeking regulatory-grade trial support.

Quantifiable outcome

  • Over 1,000 experiments conducted annually with accumulated experimental know-how and data
  • +1 more outcomes

Companies that use HLB Biostep

Customer profile

Segments3 records

Ideal customer profiles3 records

HLB Biostep technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

HLB Biostep partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core and minor.

  • ChironcoreStrategic or Co-development Partner · 27 October 2025HLB Biostep and Chiron partnered to develop next-generation non-clinical testing platforms, focusing on animal-alternative technologies to build next-gen efficacy evaluation platforms.
  • Barunseong Hospital (바른세상병원)minorStrategic or Co-development Partner · 5 May 2025Barunseong Hospital signed a preclinical trial contract with HLB Biostep and HLB Biocode, combining clinical expertise with non-clinical testing capabilities.
  • Karlsruhe Institute of Technology (KIT)minorStrategic or Co-development Partner · 28 April 2025HLB Biostep and KIT (Korea Institute of Toxicology) cooperated to build a joint research system for non-human primate (primate) testing, enhancing capabilities in primate-based preclinical studies.
  • Gradient BioconversioncoreStrategic or Co-development Partner · 13 June 2024HLB Biostep and Gradient Bioconversion partnered for the commercialization of patient-derived organoid-based drug evaluation platforms, enabling more personalized and physiologically relevant pre-clinical testing.
  • BNH InvestmentminorStrategic or Co-development Partner · 26 April 2024HLB Biostep and BNH Investment signed an MOU and hosted a Partnering Day event to identify promising biotech ventures for investment and strategic partnership opportunities.
  • ArontiercoreStrategic or Co-development Partner · 27 December 2023HLB Biostep and Arontier entered into a comprehensive business cooperation agreement to accelerate AI-driven drug development. The partnership aims to leverage AI technologies across HLB Biostep's non-clinical testing capabilities.
  • Ajou University Medical Center (아주대의료원)minorStrategic or Co-development Partner · 20 November 2023HLB Biostep signed an agreement with Ajou University Medical Center for efficacy evaluation of mental and behavioral disorder diseases, combining clinical research expertise with non-clinical testing.
  • Seoul Asan Hospital & Jeonbuk National University HospitalminorStrategic or Co-development Partner · 10 May 2023HLB Biostep signed efficacy evaluation agreements with Seoul Asan Hospital and Jeonbuk National University Hospital, enabling collaborative research combining clinical and non-clinical expertise.
  • Yonsei UniversityminorStrategic or Co-development PartnerBasgenBio is partnering with Yonsei University (alongside Dankook University) to mine clinical and omics datasets for drug targets. Listed here as a partner connected to BasgenBio's ecosystem which HLB bioStep is invested in.
  • Dankook UniversityminorStrategic or Co-development PartnerBasgenBio is partnering with Dankook University alongside Yonsei University to mine clinical and omics datasets. Listed as a partner in the broader ecosystem connected to HLB bioStep's investment in BasgenBio.

Scale indicators5 records

Recent moves6 records

Expansion highlights7 records

HLB Biostep competitors and assessment

Company assessment

Direct peers

  • Pharmaron: Integrated preclinical CRO with strong in vivo efficacy, DMPK, and safety assessment capabilities. Comparable service mix and customer focus on innovative drug developers.
  • WuXi AppTec: Major Asian-headquartered preclinical CRO offering in vivo pharmacology, DMPK, and toxicology. Comparable service breadth and target customer base of global pharma/biotech sponsors.
  • Shanghai Medicilon: China-based preclinical CRO offering in vivo efficacy, PK/PD, and toxicology services. Comparable preclinical CRO service model targeting pharma/biotech sponsors globally.
  • Crown Bioscience (JSR Life Sciences): Preclinical CRO specializing in oncology in vivo models including xenograft and syngeneic tumor models — a core capability area that directly overlaps with HLB bioStep's anti-cancer efficacy evaluation services.
  • ICR (International Contract Research): UK-headquartered preclinical CRO providing in vivo efficacy and safety studies in multiple species. Directly comparable core CRO service model.
  • Inotiv: U.S.-based preclinical CRO providing animal model services, toxicology, and research models. Closely comparable in vivo efficacy/safety testing business model.
  • Charles River Laboratories: Global leader in preclinical CRO services including in vivo efficacy and safety studies across rodent and large-animal models. Highly comparable end-to-end preclinical offering serving pharma and biotech clients.

Broad incumbents

  • Eurofins Scientific: Global testing services group with preclinical and bioanalytical capabilities alongside much broader food, environmental, and pharma testing. Comparable bioanalytical and preclinical testing services as part of a much wider portfolio.
  • Labcorp (Labcorp Drug Development / Covance): Diversified CRO offering preclinical and clinical services alongside diagnostics. Comparable preclinical efficacy/safety offering as one component of a much broader portfolio.

Emerging players

  • Biocytogen: China-based preclinical CRO with proprietary humanized mouse models and in vivo efficacy services. Comparable preclinical efficacy offering with a strong emerging-player focus on next-gen disease models.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

HLB Biostep financial estimates

Financial estimate

Revenue estimate

Valuation estimate

HLB Biostep leadership team

Management profile

Number of profiles

Profiles2 records

HLB Biostep subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

HLB Biostep funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

HLB Biostep M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HLB Biostep

What does HLB Biostep do?

HLB Biostep is Korea's first specialized non-clinical efficacy evaluation CRO, providing veterinary science-based preclinical testing services for pharmaceutical, biotech, and veterinary drug developers. Core offerings include animal-model-based efficacy evaluation across xenograft, syngeneic, and disease models; biological sample analysis using LC-MS/MS, flow cytometry, and PCR; bio-infrastructure lab design, construction, and validation; and designated veterinary drug non-clinical and clinical trial services. Services are delivered at a 11,048.69 m² Songdo research facility equipped with MRI, CT, Micro-CT, C-arm, and IVIS imaging platforms.

Is HLB Biostep a public or private company?

HLB Biostep is a public company. It is classified as public and is currently operating.

When was HLB Biostep founded?

HLB Biostep was founded in 2012.

Where is HLB Biostep based?

HLB Biostep is headquartered in Incheon, South Korea, in the Asia region.

How does HLB Biostep make money?

Three revenue lines are on record. Non-Clinical CRO Services (Efficacy & Safety Testing) is the primary driver. The others are bio-infrastructure Lab Consulting & Construction and veterinary Drug Development Services.

Who are HLB Biostep's main competitors?

Direct peers on record are Pharmaron, WuXi AppTec, Shanghai Medicilon, Crown Bioscience (JSR Life Sciences), ICR (International Contract Research), Inotiv and Charles River Laboratories. Broad incumbents are Eurofins Scientific and Labcorp (Labcorp Drug Development / Covance). Biocytogen is listed as an emerging player.

Does HLB Biostep have an API?

No public API is recorded for HLB Biostep.

What industry is HLB Biostep in?

HLB Biostep's product category is Non-Clinical Contract Research (CRO). Its primary akta.pro industry code is HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK), with a secondary code of HLAGAFAA, In Vivo Pharmacology (Efficacy/PD Models). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals